{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T21:51:13Z","timestamp":1795038673211,"version":"4.10.2"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>COVID-19 is a respiratory illness caused by SARS-CoV-2. Pharmaceutical companies aim to control virus spread through effective drugs. This study investigates chromone compound derivatives\u2019 ability to inhibit viral entry and prevent replication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This study investigated the inhibitory effect of chromone-embedded peptidomimetics and furopyrimidines on 7BZ5 from Severe Acute Respiratory Syndrome CoV-2, Homo sapiens, and 6LU7 from Bat SARS-like CoV using molecular docking. The crystal structure of these proteins was obtained from the Protein Data Bank, and the inhibition site was determined using ligand binding interaction options. The 3D structure was protonated and energetically minimised using MOE software. Chromone derivatives were designed in three dimensions, and their energy was minimised using MOE 2019. The molecular drug-likeness was calculated using SwissADME, Lipinski and Benigni-Bossa\u2019s rule, and toxicity was calculated using Toxtree v3.1.0 software. Compounds with pharmacological properties were selected for molecular docking, and interactions were assessed using MOE 2019. MD simulations of Mpro-ch-p complexes were performed to evaluate root mean square fluctuations (RMSF) and measure protein stability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>The pharmacokinetic tests revealed that chromone derivatives of the peptidomimetic family have acceptable pharmacokinetic activity in the human body. Some compounds, such as Ch-p1, Ch-p2, Ch-p6, Ch-p7, Ch-p12, and Ch-p13, have pronounced medicinal properties. Molecular docking revealed high affinity for binding to SARS-CoV-2 protease. Ch-p7 had the highest binding energy, likely due to its inhibitory property. A 10\u00a0ns molecular dynamics study confirmed the stability of the protein\u2013ligand complex, resulting in minimal fluctuations in the system's backbone. The MM-GBSA analysis revealed free energies of binding of \u2212\u200919.54\u00a0kcal\/mol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study investigated the inhibition of viral replication using chromone derivatives, finding high inhibitory effects in the peptidomimetic family compared to other studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-023-06508-7","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T10:03:51Z","timestamp":1695290631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Chromone-embedded peptidomimetics and furopyrimidines as highly potent SARS-CoV-2 infection inhibitors: docking and MD simulation study"],"prefix":"10.1186","volume":"16","author":[{"given":"Zahra","family":"Shakibay Senobari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Masoumian Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Bagher","family":"Teimouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Hossein","family":"Rezayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Samarghandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Hekmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"6508_CR1","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2021.146134","volume":"814","author":"V Papanikolaou","year":"2022","unstructured":"Papanikolaou V, Chrysovergis A, Ragos V, Tsiambas E, Katsinis S, Manoli A, Papouliakos S, Roukas D, Mastronikolis S, Peschos D, et al. From delta to Omicron: S1-RBD\/S2 mutation\/deletion equilibrium in SARS-CoV-2 defined variants. Gene. 2022;814: 146134.","journal-title":"Gene"},{"issue":"7798","key":"6508_CR2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270\u20133.","journal-title":"Nature"},{"issue":"10224","key":"6508_CR3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The lancet. 2020;395(10224):565\u201374.","journal-title":"The lancet"},{"key":"6508_CR4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727\u201333.","journal-title":"N Engl J Med"},{"issue":"10223","key":"6508_CR5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. The lancet. 2020;395(10223):470\u20133.","journal-title":"The lancet"},{"key":"6508_CR6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.coviro.2014.01.010","volume":"5","author":"VS Raj","year":"2014","unstructured":"Raj VS, Osterhaus AD, Fouchier RA, Haagmans BL. MERS: emergence of a novel human coronavirus. Curr Opin Virol. 2014;5:58\u201362.","journal-title":"Curr Opin Virol"},{"issue":"7592","key":"6508_CR7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature17200","volume":"531","author":"RN Kirchdoerfer","year":"2016","unstructured":"Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, Corbett KS, Graham BS, McLellan JS, Ward AB. Pre-fusion structure of a human coronavirus spike protein. Nature. 2016;531(7592):118\u201321.","journal-title":"Nature"},{"issue":"4","key":"6508_CR8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1139\/y02-021","volume":"80","author":"AJ Turner","year":"2002","unstructured":"Turner AJ, Tipnis SR, Guy JL, Rice GI, Hooper NM. ACEH\/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol. 2002;80(4):346\u201353.","journal-title":"Can J Physiol Pharmacol"},{"issue":"6965","key":"6508_CR9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450\u20134.","journal-title":"Nature"},{"issue":"6485","key":"6508_CR10","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444\u20138.","journal-title":"Science"},{"key":"6508_CR11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fcimb.2020.00317","volume":"10","author":"L Samavati","year":"2020","unstructured":"Samavati L, Uhal BD. ACE2, much more than just a receptor for SARS-COV-2. Front Cell Infect Microbiol. 2020;10:317.","journal-title":"Front Cell Infect Microbiol"},{"key":"6508_CR12","volume-title":"Fields virology","author":"D Knipe","year":"2013","unstructured":"Knipe D, Howley P, Cohen J, Griffin D, Lamb R, Martin M, Racaniello V, Roizman B. Fields virology. Philadelphia: Lippincott Williams & Wilkins; 2013."},{"issue":"6496","key":"6508_CR13","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","volume":"368","author":"Y Wu","year":"2020","unstructured":"Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, Li Z, Li S, Bi Y, Yang Y. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. 2020;368(6496):1274\u20138.","journal-title":"Science"},{"issue":"7811","key":"6508_CR14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289\u201393.","journal-title":"Nature"},{"issue":"7798","key":"6508_CR15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-Y. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265\u20139.","journal-title":"Nature"},{"issue":"3","key":"6508_CR16","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1099\/0022-1317-83-3-595","volume":"83","author":"A Hegyi","year":"2002","unstructured":"Hegyi A, Ziebuhr J. Conservation of substrate specificities among coronavirus main proteases. J Gen Virol. 2002;83(3):595\u20139.","journal-title":"J Gen Virol"},{"issue":"14","key":"6508_CR17","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","volume":"59","author":"T Pillaiyar","year":"2016","unstructured":"Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung S-H. An overview of severe acute respiratory syndrome\u2013coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J Med Chem. 2016;59(14):6595\u2013628.","journal-title":"J Med Chem"},{"issue":"5","key":"6508_CR18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.5582\/bst.2021.01346","volume":"15","author":"Y Shao","year":"2021","unstructured":"Shao Y, Chen J, Lu H. Update: drug treatment options for coronavirus disease 2019 (COVID-19). Biosci Trends. 2021;15(5):345\u20139.","journal-title":"Biosci Trends"},{"issue":"5","key":"6508_CR19","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.3390\/cells10051052","volume":"10","author":"RH Pirzada","year":"2021","unstructured":"Pirzada RH, Haseeb M, Batool M, Kim M, Choi S. Remdesivir and ledipasvir among the FDA-approved antiviral drugs have potential to inhibit SARS-CoV-2 replication. Cells. 2021;10(5):1052.","journal-title":"Cells"},{"issue":"2","key":"6508_CR20","first-page":"132","volume":"63","author":"R Chaudhary","year":"2020","unstructured":"Chaudhary R, Bhyan SJ, Bhyan B, Thomas B, Gupta AN, Hamid K. Review on remdesivir: a possible therapeutic option for the COVID-19. Int J Pharm Sci Rev Res. 2020;63(2):132\u20136.","journal-title":"Int J Pharm Sci Rev Res"},{"issue":"1","key":"6508_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jppr.1799","volume":"52","author":"JA Roberts","year":"2022","unstructured":"Roberts JA, Duncan A, Cairns KA. Pandora\u2019s box: Paxlovid, prescribing, pharmacists and pandemic. J Pharm Pract Res. 2022;52(1):1.","journal-title":"J Pharm Pract Res"},{"key":"6508_CR22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-3-030-31269-5_9","volume-title":"Medicinal plants: from farm to pharmacy","author":"A-M Reid","year":"2019","unstructured":"Reid A-M, Lall N. Natural products as possible vaccine adjuvants for infectious diseases and cancer. In: Medicinal plants: from farm to pharmacy. Springer; 2019. p. 187\u2013213."},{"key":"6508_CR23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s11101-020-09681-w","volume":"19","author":"RB Semwal","year":"2020","unstructured":"Semwal RB, Semwal DK, Combrinck S, Viljoen A. Health benefits of chromones: common ingredients of our daily diet. Phytochem Rev. 2020;19:761\u201385.","journal-title":"Phytochem Rev"},{"issue":"1","key":"6508_CR24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/14786419.2019.1678618","volume":"34","author":"A Nazhand","year":"2020","unstructured":"Nazhand A, Durazzo A, Lucarini M, Romano R, Mobilia MA, Izzo AA, Santini A. Human health-related properties of chromones: an overview. Nat Prod Res. 2020;34(1):137\u201352.","journal-title":"Nat Prod Res"},{"issue":"8","key":"6508_CR25","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1055-9965.EPI-06-0017","volume":"15","author":"M Rossi","year":"2006","unstructured":"Rossi M, Negri E, Talamini R, Bosetti C, Parpinel M, Gnagnarella P, Franceschi S, Dal Maso L, Montella M, Giacosa A. Flavonoids and colorectal cancer in Italy. Cancer Epidemiol Prev Biomark. 2006;15(8):1555\u20138.","journal-title":"Cancer Epidemiol Prev Biomark"},{"issue":"10","key":"6508_CR26","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1021\/ol0703736","volume":"9","author":"JA Chemler","year":"2007","unstructured":"Chemler JA, Yan Y, Leonard E, Koffas MA. Combinatorial mutasynthesis of flavonoid analogues from acrylic acids in microorganisms. Org Lett. 2007;9(10):1855\u20138.","journal-title":"Org Lett"},{"issue":"5","key":"6508_CR27","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s11224-020-01537-5","volume":"31","author":"N Sepay","year":"2020","unstructured":"Sepay N, Sepay N, Al Hoque A, Mondal R, Halder UC, Muddassir M. In silico fight against novel coronavirus by finding chromone derivatives as inhibitor of coronavirus main proteases enzyme. Struct Chem. 2020;31(5):1831\u201340.","journal-title":"Struct Chem"},{"key":"6508_CR28","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3389\/fphar.2020.00854","volume":"11","author":"P Sestili","year":"2020","unstructured":"Sestili P, Stocchi V. Repositioning chromones for early anti-inflammatory treatment of COVID-19. Front Pharmacol. 2020;11:854.","journal-title":"Front Pharmacol"},{"issue":"4","key":"6508_CR29","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jpha.2020.04.008","volume":"10","author":"MU Mirza","year":"2020","unstructured":"Mirza MU, Froeyen M. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. J Pharm Anal. 2020;10(4):320\u20138.","journal-title":"J Pharm Anal"},{"key":"6508_CR30","volume-title":"Molecular operating environment (MOE)","author":"Inc CCG","year":"2016","unstructured":"Inc CCG. Molecular operating environment (MOE). Montreal: Chemical Computing Group Inc.; 2016."},{"key":"6508_CR31","volume-title":"Review of software tools for toxicity prediction","author":"MF Gatnik","year":"2010","unstructured":"Gatnik MF, Worth AP. Review of software tools for toxicity prediction. Luxembourg: Publications Office of the European Union; 2010."},{"issue":"1","key":"6508_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):1\u201313.","journal-title":"Sci Rep"},{"issue":"1","key":"6508_CR33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","volume":"44","author":"CA Lipinski","year":"2000","unstructured":"Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235\u201349.","journal-title":"J Pharmacol Toxicol Methods"},{"key":"6508_CR34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.addr.2016.04.029","volume":"101","author":"CA Lipinski","year":"2016","unstructured":"Lipinski CA. Rule of five in 2015 and beyond: target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Adv Drug Deliv Rev. 2016;101:34\u201341.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"6508_CR35","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1021\/jm5019093","volume":"58","author":"JL Dahlin","year":"2015","unstructured":"Dahlin JL, Nissink JWM, Strasser JM, Francis S, Higgins L, Zhou H, Zhang Z, Walters MA. PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. J Med Chem. 2015;58(5):2091\u2013113.","journal-title":"J Med Chem"},{"issue":"11","key":"6508_CR36","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.4155\/fmc.14.60","volume":"6","author":"JL Dahlin","year":"2014","unstructured":"Dahlin JL, Walters MA. The essential roles of chemistry in high-throughput screening triage. Future Med Chem. 2014;6(11):1265\u201390.","journal-title":"Future Med Chem"},{"issue":"5","key":"6508_CR37","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/20024091064273","volume":"32","author":"J Hukkanen","year":"2002","unstructured":"Hukkanen J, Pelkonen O, Hakkola J, Raunio H. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol. 2002;32(5):391\u2013411.","journal-title":"Crit Rev Toxicol"},{"issue":"1","key":"6508_CR38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13578-022-00794-7","volume":"12","author":"L Li","year":"2022","unstructured":"Li L, Gao M, Jiao P, Zu S, Deng Y-Q, Wan D, Cao Y, Duan J, Aliyari SR, Li J, et al. Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants. Cell Biosci. 2022;12(1):63.","journal-title":"Cell Biosci"},{"issue":"14","key":"6508_CR39","doi-asserted-by":"crossref","first-page":"6984","DOI":"10.1128\/JVI.00442-08","volume":"82","author":"F Li","year":"2008","unstructured":"Li F. Structural analysis of major species barriers between humans and palm civets for severe acute respiratory syndrome coronavirus infections. J Virol. 2008;82(14):6984\u201391.","journal-title":"J Virol"},{"issue":"12","key":"6508_CR40","doi-asserted-by":"crossref","first-page":"8904","DOI":"10.1074\/jbc.M111.325803","volume":"287","author":"K Wu","year":"2012","unstructured":"Wu K, Peng G, Wilken M, Geraghty RJ, Li F. Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus. J Biol Chem. 2012;287(12):8904\u201311.","journal-title":"J Biol Chem"},{"issue":"7807","key":"6508_CR41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221\u20134.","journal-title":"Nature"},{"issue":"17","key":"6508_CR42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127377","volume":"30","author":"S Ullrich","year":"2020","unstructured":"Ullrich S, Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett. 2020;30(17): 127377.","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"6508_CR43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/md18040225","volume":"18","author":"D Gentile","year":"2020","unstructured":"Gentile D, Patamia V, Scala A, Sciortino MT, Piperno A, Rescifina A. Putative inhibitors of SARS-CoV-2 main protease from a library of marine natural products: a virtual screening and molecular modeling study. Mar Drugs. 2020;18(4):225.","journal-title":"Mar Drugs"},{"key":"6508_CR44","doi-asserted-by":"crossref","first-page":"622898","DOI":"10.3389\/fchem.2021.622898","volume":"9","author":"HM Mengist","year":"2021","unstructured":"Mengist HM, Dilnessa T, Jin T. Structural basis of potential inhibitors targeting SARS-CoV-2 main protease. Front Chem. 2021;9:622898.","journal-title":"Front Chem"},{"issue":"3","key":"6508_CR45","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3906\/kim-2012-55","volume":"45","author":"Z Ger\u00e7ek","year":"2021","unstructured":"Ger\u00e7ek Z, Ceyhan D, Er\u00e7a\u011f E. Synthesis and molecular docking study of novel COVID-19 inhibitors. Turk J Chem. 2021;45(3):704\u201318.","journal-title":"Turk J Chem"},{"issue":"1","key":"6508_CR46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1515\/chem-2021-0024","volume":"19","author":"MH Abdellatiif","year":"2021","unstructured":"Abdellatiif MH, Ali A, Ali A, Hussien MA. Computational studies by molecular docking of some antiviral drugs with COVID-19 receptors are an approach to medication for COVID-19. Open Chem. 2021;19(1):245\u201364.","journal-title":"Open Chem"},{"issue":"1","key":"6508_CR47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s13337-021-00683-6","volume":"32","author":"U Rutwick Surya","year":"2021","unstructured":"Rutwick Surya U, Praveen N. A molecular docking study of SARS-CoV-2 main protease against phytochemicals of Boerhavia diffusa Linn. for novel COVID-19 drug discovery. Virus Dis. 2021;32(1):46\u201354.","journal-title":"Virus Dis"},{"issue":"1","key":"6508_CR48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s10600-020-02943-1","volume":"56","author":"L-M Liao","year":"2020","unstructured":"Liao L-M, Sun Y-Q, Li J, Kong W-S, Liu X, Xu Y, Huang H-T, Zeng W-L, Mi Q-L, Yang G-Y. Two new chromone derivatives from cassia nomame and their anti-tobacco mosaic virus activity. Chem Nat Compd. 2020;56(1):58\u201361.","journal-title":"Chem Nat Compd"},{"issue":"37","key":"6508_CR49","doi-asserted-by":"crossref","first-page":"10819","DOI":"10.1021\/acs.jafc.1c03626","volume":"69","author":"N Zan","year":"2021","unstructured":"Zan N, Li J, He H, Hu D, Song B. Discovery of novel chromone derivatives as potential anti-TSWV agents. J Agric Food Chem. 2021;69(37):10819\u201329.","journal-title":"J Agric Food Chem"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-023-06508-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-023-06508-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-023-06508-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T17:17:43Z","timestamp":1700500663000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-023-06508-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6508"],"URL":"https:\/\/doi.org\/10.1186\/s13104-023-06508-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2555399\/v1","asserted-by":"object"}]},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"6 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All information is based on machine and software-assisted predictions. No human or animal data were used for the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"224"}}